Slideshow

Antipsychotic Augmentation vs Monotherapy in Schizophrenia

Author(s):

Brian Miller, MD, PhD, MPH

To augment or not to augment? That is the question.

View the slides in PDF format. Also see: Antipsychotics and Breast Cancer Risk.

Related Videos
Muskin
lithium
McIntyre
John Krystal
Meyer
emergency
Related Content
Shaheen Lakhan, MD, PhD
June 19th 2025

Marking Progress, Promise of Prescription Digital Therapeutics for Mental Health: Interview with Shaheen Lakhan, MD, PhD

Kenneth J. Bender, PharmD, MA
Here's to a Psychedelic Revolution
April 9th 2022

Here's to a Psychedelic Revolution

Amir Inamdar MBBS, DNB (Psych), MFPM
FDA
June 16th 2025

FDA Officially Eliminates Clozapine REMS

Leah Kuntz
Blue Light Blockers: A Behavior Therapy for Mania
October 7th 2021

Blue Light Blockers: A Behavior Therapy for Mania

Chris Aiken, MD Kellie Newsome, PMH-NP
learning
June 12th 2025

How Do Psychiatry Residents Learn Psychopharmacology?

Joseph F. Goldberg, MD Stephen M. Stahl, MD, PhD, DSc (Hon)
antidepressants hesitation
June 5th 2025

Is Psychiatry Corrupt? Aftab and Antidepressants

Daniel Morehead, MD
© 2025 MJH Life Sciences

All rights reserved.